HRC - Hill-Rom Holdings, Inc.
| Previous Close | 108.63 |
| Open | 108.86 |
| Bid | 109.27 x 1000 |
| Ask | 109.99 x 1000 |
| Day's Range | 107.94 - 109.47 |
| 52 Week Range | 93.88 - 117.10 |
| Volume | 194,214 |
| Avg. Volume | 405,754 |
| Market Cap | 7.333B |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | 49.31 |
| EPS (TTM) | 2.22 |
| Earnings Date | Apr 23, 2020 - Apr 27, 2020 |
| Forward Dividend & Yield | 0.84 (0.77%) |
| Ex-Dividend Date | Dec 12, 2019 |
| 1y Target Est | 125.78 |
- Thomson Reuters StreetEvents
Edited Transcript of HRC earnings conference call or presentation 26-Jan-18 1:30pm GMT
Q1 2018 Hill-Rom Holdings Inc Earnings Call
- Simply Wall St.
Announcing: Hill-Rom Holdings (NYSE:HRC) Stock Increased An Energizing 131% In The Last Five Years
The worst result, after buying shares in a company (assuming no leverage), would be if you lose all the money you put...
- Zacks
Here's Why You Should Add Zimmer (ZBH) to Your Portfolio
Investors continue to be optimistic about Zimmer's (ZBH) potential on its strong segmental and international results for the fiscal fourth quarter.
- Zacks
Hologic Expands Panther Portfolio With New Product Offerings
Hologic's (HOLX) latest offerings are set to improve flexibility and efficiency of laboratories.
- Zacks
ResMed (RMD) Rides on New Product Portfolio, SaaS Growth
Within SaaS, ResMed (RMD) consistently gains momentum from the Brightree service portfolio and derives synergies from the accretive MatrixCare buyout.
- Zacks
Here's Why You Should Add ResMed (RMD) to Your Portfolio
Investors continue to be optimistic about ResMed (RMD), given its strong segmental and international fiscal second-quarter results.
- Zacks
QIAGEN Launches CE-Marked Breast Cancer Test Kit in Europe
QIAGEN (QGEN) launches latest diagnostics test kit in Europe to combat advanced breast cancer, following the CE Mark receipt.
- Zacks
ResMed (RMD) Stock Hits New 52-Week High: What's Driving It?
ResMed (RMD) is optimistic about maintaining growth momentum on several recent developments.
- Zacks
Medtronic's Cobalt, Crome Heart Devices Portfolio Gets CE Mark
Medtronic's (MDT) next generation BlueSync-enabled implantable heart devices, which incorporate upgraded features, receive CE mark.
- Zacks
Align (ALGN) Rides on Volume Expansion Despite Cost Concerns
We are upbeat about Align's (ALGN) consistent uptrend in Invisalign volumes across all geographies.
- Zacks
Here's Why You Should Hold on to Hologic (HOLX) Stock for Now
Investors continue to be optimistic about Hologic (HOLX) on its strong segmental and international results in Q1.
- Zacks
HRC vs. BSX: Which Stock Should Value Investors Buy Now?
HRC vs. BSX: Which Stock Is the Better Value Option?
- Zacks
Quest Diagnostics (DGX) Hits a 52-Week High: What's Driving the Stock?
Quest Diagnostics (DGX) gains from several positive developments like partnerships and acquisitions.
- Zacks
Teleflex's Bipolar Temporary Pacing Guidewire Gets FDA Nod
Teleflex (TFX) receives the FDA clearance for its bipolar temporary pacing guidewire, thus paving the way for improvements in TAVR and BAV procedures.
- Zacks
Quest Diagnostics to Buy Select Assets of Memorial Hermann
The acquisition is a step forward in Quest Diagnostics' (DGX) commitment toward offering high-quality, cost-efficient diagnostic services in Texas,especially the Houston metropolitan area.
- Thomson Reuters StreetEvents
Edited Transcript of HRC earnings conference call or presentation 24-Jan-20 1:30pm GMT
Q1 2020 Hill-Rom Holdings Inc Earnings Call
- Zacks
New Alliances Aid Quest Diagnostics Despite Reimbursement Woes
Quest Diagnostics (DGX) is currently concentrating on diagnostic information services arm and disciplined capital deployment.
- Zacks
Hill-Rom's (HRC) Q1 Earnings Top Estimates, Revenues In Line
Sales in Hill-Rom's (HRC) Surgical Solutions suffer a massive setback, thanks to the divestiture of surgical consumables.
- Zacks
Hill-Rom (HRC) Tops Q1 Earnings Estimates
Hill-Rom (HRC) delivered earnings and revenue surprises of 4.63% and -0.04%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
- PR Newswire
Hillrom Announces Fiscal First Quarter Financial Results
Hillrom (NYSE: HRC), today announced financial results for its fiscal first quarter ended December 31, 2019, confirmed its fiscal 2020 revenue guidance and raised the bottom of its adjusted earnings per diluted share guidance range.
- Zacks
New Product Suite Boosts Intersect ENT Despite Cost Concerns
With respect to Intersect ENT's (XENT) Propel line, the PROPEL suite scores as the standard of care for polyp patients undergoing sinus surgery.
- Zacks
Zimmer (ZBH) Stock Hits New 52-Week High: What's Driving It?
Zimmer (ZBH) is optimistic about maintaining its growth momentum on several recent developments.
- Zacks
Medtronic (MDT) Gets FDA Nod for Micra AV to Treat AV Block
Medtronic's (MDT) Micra AV cleared by the FDA for the treatment of AV block in patients eligible for pacemaker implantation.
- Zacks
Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark
We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.
- Zacks
Zimmer Biomet Rides on Product Launches Despite Pricing Woes
Zimmer Biomet's (ZBH) execution of its priority agenda including quality remediation, supply recovery efforts and product introductions looks impressive.
